Engineering immune cells to better fight solid tumors
Project 3
This study is looking at how we can make your own immune cells, called T cells, even better at fighting tough solid tumors in cancer, using special tools to help them work more effectively, with the hope of creating stronger treatments for people with aggressive cancers.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10896032 on NIH RePORTER |
What this research studies
This research focuses on improving cancer treatment by modifying a patient's own immune cells, specifically T cells, to better target and destroy solid tumors. The approach utilizes advanced techniques like CRISPR/Cas9 for precise gene editing, allowing researchers to enhance the T cells' ability to navigate the challenging environment of solid tumors. By overcoming the barriers that limit the effectiveness of current therapies, this project aims to develop more effective treatments for patients with aggressive cancers. The research involves both laboratory work and potential clinical applications, aiming for durable cures.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who have not responded well to existing therapies.
Not a fit: Patients with non-solid tumors or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using CRISPR technology for T cell engineering, indicating potential for success in this novel approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Moriarity, Branden S — University of Minnesota
- Study coordinator: Moriarity, Branden S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.